指南与共识神经介入DSA

因基础动脉粥样硬化行颅内支架置入时抗血小板管理的德尔菲共识声明:机械取栓背景下的专家意见

A DELPHI consensus statement on antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of mechanical thrombectomy.
指南 / 共识 · Neuroradiology · 2020-09-24

本研究采用改良德尔菲法,由来自8个国家的19名神经介入专家通过5轮匿名问卷,评估在血管内治疗背景下因基础颅内动脉粥样硬化行颅内支架置入时抗血小板管理能否达成共识。专家们承认该领域证据不足,但在术后抗血小板方案上达成共识,而术前和术中方案未达成共识,并认为需要进一步前瞻性研究来优化方案。

要点

  • 专家共识认为抗血小板管理应遵循标准化方案, irrespective of imaging findings and reperfusion quality。
  • 围手术期首选阿司匹林,术后首选口服阿司匹林联合P2Y12抑制剂。
  • 关于抗血小板治疗启动时机未达成共识,术前和术中方案也未达成共识。

诊断标准与关键数值

  • 专家组共识定义为二分类封闭式问题同意率≥70%,多选项封闭式问题同意率≥50%。

临床应用与阅片要点

  • 专家组认为抗血小板管理应遵循标准化方案, irrespective of imaging findings and reperfusion quality。
  • 围手术期首选抗血小板药物为阿司匹林。
  • 术后首选方案为口服阿司匹林联合P2Y12抑制剂。
  • 关于抗血小板治疗启动时机未达成共识。

局限性

  • 专家组承认在许多方面缺乏证据基础推荐的数据。
  • 关于抗血小板治疗启动时机未达成共识。
  • 术前和术中抗血小板方案未达成共识。
  • 需要进一步前瞻性研究来优化抗血小板方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: There is little data and lack of consensus regarding antiplatelet management for intracranial stenting due to underlying intracranial atherosclerosis in the setting of endovascular treatment (EVT). In this DELPHI study, we aimed to assess whether consensus on antiplatelet management in this situation among experienced experts can be achieved, and what this consensus would be.

METHODS: We used a modified DELPHI approach to address unanswered questions in antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of EVT. An expert-panel (19 neurointerventionalists from 8 countries) answered structured, anonymized on-line questionnaires with iterative feedback-loops. Panel-consensus was defined as agreement ≥ 70% for binary closed-ended questions/≥ 50% for closed-ended questions with > 2 response options.

RESULTS: Panel members answered a total of 5 survey rounds. They acknowledged that there is insufficient data for evidence-based recommendations in many aspects of antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of EVT. They believed that antiplatelet management should follow a standardized regimen, irrespective of imaging findings and reperfusion quality. There was no consensus on the timing of antiplatelet-therapy initiation. Aspirin was the preferred antiplatelet agent for the peri-procedural period, and oral Aspirin in combination with a P2Y12 inhibitor was the favored postprocedural regimen.

CONCLUSION: Data on antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of EVT are limited. Panel-members in this study achieved consensus on postprocedural antiplatelet management but did not agree upon a preprocedural and intraprocedural antiplatelet regimen. Further prospective studies to optimize antiplatelet regimens are needed.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Goyal M, Orlov K, Jensen ME, et al. A DELPHI consensus statement on antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of mechanical thrombectomy. Neuroradiology. 2020. PMID: 32974691. doi:10.1007/s00234-020-02556-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。